drugset / Trial / NCT04751955
A Phase lb/ll, Open Label, Single Arm Study With Olinvacimab and Capecitabine in mCRC Patients (OLCAP)
NaSingle-groupOpen-labelTreatment
Summary
The aim on this study is to assess the safety and efficacy of the anti-VEGFR2 monoclonal antibody olinvacimab and the capecitabine in patients with metastatic colorectal carcinoma who failed two prior chemotherapies
Timeline
- Start
- 2022-01-01
- Primary completion
- 2023-10-31
- Completion
- 2024-08-31
Outcome
Outcome not reported
Stopped: “This clinical trial was not finally approved by the Korea FDA.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Olinvacimab | Monoclonal antibody | 12 mg/kg | Intravenous |
| Subject | Olinvacimab | Monoclonal antibody | 16 mg/kg | Intravenous |